Tonix Pharmaceuticals Holding Corp (TNXP) Unusual Options Activity Today

Checking TNXP unusual options activity helps you spot when traders are making outsized bets on Tonix Pharmaceuticals Holding Corp before the broader market catches on. Tonix Pharmaceuticals Holding Corp's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor TNXP unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching TNXP unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking TNXP unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and TNXP unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases.

Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Catalysts rarely arrive without a footprint, and TNXP unusual options activity is often where that footprint shows up first. Our scanner tracks Tonix Pharmaceuticals Holding Corp's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at TNXP unusual options volume on the call side or chasing put sweeps, Tonix Pharmaceuticals Holding Corp's unusual options flow today is one click away, so put it on your radar before the headlines hit.